by Raynovich Rod | Apr 27, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Update 4/6/16 Biotech Rally Picks Up Momentum Today IBB up 4.5%,XBI up 5% Speculative stocks lead the way: BLUE up 10%, VRX up 16.6% ——–Risk on mode continues——— Healthcare Sector Leads the Market Lagging healthcare and biotech...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Roche/Genentech Has a Strong Pipeline in Diagnostics and Therapeutics to Drive Moderate Growth in 2016 New Stock Pick: Roche Holding (OTCQX:RHHBY) $30.36 Over the past 3 months we recommended several new buys for the Rayno Biopharma Portfolio emphasizing moderate...
by Raynovich Rod | Mar 14, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Tuesday 12:45pm EDT Update on a red screen day: Healthcare sector lags down 1.6%, biotechs now being crushed IBB down 3.1%,XBI down 5%! ——– Look for Value +Growth Picks in a Biotech Bear Market Marijuana Strengthens Clinical Status Review our...
by Raynovich Rod | Feb 2, 2016 | 2024 Rayno Biopharmaceuticals Portfolio
Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug...
by Raynovich Rod | Feb 1, 2016 | 2024 Rayno Tools and Diagnostics Portfolio
Abbott Laboratories Acquires Alere (ALR) -Stock Soars 45% At Market Opening Alere Product Line Offers Synergies and Boosts Global Diagnostics Presence 2015 Revenues of Alere Are Estimated in $2.5B Range So Deal is About 2.3X Sales Alere (ALR) has a broad-based product...
by Raynovich Rod | Jan 5, 2016 | Biopharmaceuticals
Update-1… 3P EST -Biotechs Sink Further XBI Down 5%, IBB down 2.34% Green stocks are hard to find: GILD, HOLX, REGN Biotech Bear Market: Lackluster Tape Says Wait Until Next Week For Market Direction Year-End Rally Fizzles in New Year Biotech stocks (IBB) are...
by Raynovich Rod | Jan 3, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015 and the Mid-Caps also beat despite a big loss by Clovis Oncology...
by Raynovich Rod | Dec 28, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biopharma Rally On Hold When you read the Transfs online trading guide, you will begin to understand that trading can be a volatile investment. There will be amazing days, weeks, or months where rates are perfect for you but there will also be days, weeks, or months...
by Raynovich Rod | Dec 10, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Tradeable Intermediate Bottom Today 12:36P… 12/15 GILD 102.8,IBB 331 Update at Close Update…Sunday 12/13/15…Grim Outlook…Risk Off The market sunk further Friday afternoon after 3p for a NASDAQ close at 4933 off 2.33% (up 4.17% YTD) for the...